CBP 5002
Alternative Names: CBP-5002Latest Information Update: 12 Jul 2022
At a glance
- Originator Coherent Biopharma (Suzhou)
- Class Drug conjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 24 Jun 2022 New profile created based on Coherent Biopharma pipeline; 20 June 2022
- 24 Jun 2022 Preclinical trials in Unspecified in China (Unspecified) (Coherent Biopharma pipeline; June 2022)